Paper · 42650797

MASLD: Spatial Mechanisms and New Therapeutics.

Stoess C and 6 others. Biomolecules, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. MASLD: Spatial Mechanisms and New Therapeutics. Papers, record 42650797. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42650797

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: MASLD: Spatial Mechanisms and New Therapeutics.; PubMed
Journal: Biomolecules; PubMed
Year: 2026; PubMed
Publication types: Journal Article, Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/42650797/; PubMed
DOI: https://doi.org/10.3390/biom16081129; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13510284/; PubMed
The journal: https://conductscience.org/library/journal-index/101596414; PubMed
Citations, by iCite: 0; iCite
Revised in PubMed: 2026-08-30; PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Stoess C	Christian	https://orcid.org/0000-0002-0682-8808
2	Onyuru J	Janset	https://orcid.org/0000-0003-3924-8487
3	Hu Y	Yanzhu	https://orcid.org/0000-0002-5580-2938
4	Jiang Y	Yuan
5	Xin Z	Zhengyi
6	Panchal A	Aryan
7	Hartmann P	Phillipp

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Fatty Liver	Major topic
Non-alcoholic Fatty Liver Disease	Major topic
Humans
Animals
Liver
Hepatic Stellate Cells
Hepatocytes
Liver Cirrhosis

Source PubMed

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
1K12HD105271-01	NIH HHS	United States	K12HD105271	PubMed	NIH RePORTER
P30 DK120515	NIDDK NIH HHS	United States	P30DK120515	PubMed	NIH RePORTER
K12 HD105271	NICHD NIH HHS	United States	K12HD105271	PubMed	NIH RePORTER
KL2 TR001444	NCATS NIH HHS	United States	KL2TR001444	PubMed	NIH RePORTER
KL2TR001444	Altman Clinical and Translational Research Institute (ACTRI)		KL2TR001444	PubMed	NIH RePORTER
P30 DK120515	San Diego Digestive Diseases Research Center		P30DK120515	PubMed	NIH RePORTER
Pinnacle Research Award in Liver Diseases Grant PNC22-159963	American Association for the Study of Liver Diseases			PubMed	PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References147

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	41,986,723	A spatial atlas of the healthy human liver from live donors.	Nature	2026	https://conductscience.org/library/papers/41986723	PubMed
2	38,298,161	Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease.	Gut Microbes	2024	https://conductscience.org/library/papers/38298161	PubMed
3	22,297,845	Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.	Nature	2012	https://conductscience.org/library/papers/22297845	PubMed
4	25,125,077	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.	Hepatology	2015	https://conductscience.org/library/papers/25125077	PubMed
5	29,629,177	Risk factors for progression of and treatment options for NAFLD in children.	Clin Liver Dis (Hoboken)	2018	https://conductscience.org/library/papers/29629177	PubMed
6	38,851,997	EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).	J Hepatol	2024	https://conductscience.org/library/papers/38851997	PubMed
7	41,564,158	Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis.	Sci Transl Med	2026	https://conductscience.org/library/papers/41564158	PubMed
8	38,967,596	Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment.	Hepatol Commun	2024	https://conductscience.org/library/papers/38967596	PubMed
9	30,559,024	Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity.	J Pediatr	2019	https://conductscience.org/library/papers/30559024	PubMed
10	40,142,567	Faecalibacterium prausnitzii Is Associated with Disease Severity in MASLD but Its Supplementation Does Not Improve Diet-Induced Steatohepatitis in Mice.	Microorganisms	2025	https://conductscience.org/library/papers/40142567	PubMed

1 to 10 of 147

See all 147 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42650797

GET https://conductscience.org/api/papers/v1/42650797/references?page=2

API reference For AI assistants